To generate the hyrbidomas, 10-week-old, female BALB/c mice received an initial injection of ILT3 human IgG1 fusion protein mixed with Alu-Gel-S behind the neck. 4 weeks later, they were given a booster immunization with the same immunogen, followed after 2 weeks by a final injection of purified ILT3 human IgG1 fusion. 3 days later, mice were killed and draining lymph node cells were isolated and fused with the myeloma fusion partner. Hybridoma supernatants were screened by ELISA and FACS analysis. Since ILT3 is expressd on myeloid antigen presenting cells (APC), these hybridomas can be used to study how APC activation is regulated.
